enGene Therapeutics Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
enGene Therapeutics Inc. (ENGN) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-09-08
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2026-07-31 was $0.00.
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2026-04-30 was $0.00.
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2026-01-31 was $0.00.
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-10-31 was $0.00.
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $0.00.
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $0.00.
- enGene Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-07-31 | $0.00 10-Q · filed 2026-09-08 | $0.00 derived: sum of 2 quarters · filed 2026-09-08 | $0.00 10-Q · filed 2026-09-08 | $0.00 derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | $0.00 10-Q · filed 2026-06-15 | $0.00 10-Q · filed 2026-06-15 | $0.00 derived: sum of 3 quarters · filed 2026-06-15 | $0.00 derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | $0.00 10-Q · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-09-08 | $0.00 derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-08 | $0.00 derived: sum of 3 quarters · filed 2026-09-08 | $0.00 10-K · filed 2025-12-22 |
| 2025-07-31 | $0.00 10-Q · filed 2026-09-08 | $0.00 derived: sum of 2 quarters · filed 2026-09-08 | $0.00 10-Q · filed 2026-09-08 | $0.00 derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | $0.00 10-Q · filed 2026-06-15 | $0.00 10-Q · filed 2026-06-15 | $0.00 derived: sum of 3 quarters · filed 2026-06-15 | $0.00 derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | $0.00 10-Q · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $0.00 derived: sum of 2 quarters · filed 2025-12-22 | $0.00 derived: sum of 3 quarters · filed 2025-12-22 | $0.00 10-K · filed 2025-12-22 |
| 2024-07-31 | $0.00 10-Q · filed 2025-09-11 | $0.00 derived: sum of 2 quarters · filed 2025-09-11 | $0.00 10-Q · filed 2025-09-11 | |
| 2024-04-30 | $0.00 10-Q · filed 2025-06-12 | $0.00 10-Q · filed 2025-06-12 | ||
| 2024-01-31 | $0.00 10-Q · filed 2025-03-10 | |||
| 2023-10-31 | $0.00 10-K · filed 2024-12-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |